Anticoagulant treatment in COVID-19: a narrative review

59Citations
Citations of this article
227Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The actual Coronavirus Disease (COVID 19) pandemic is due to Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the coronavirus family. Besides the respiratory involvement, COVID 19 patients frequently develop a pro-coagulative state caused by virus-induced endothelial dysfunction, cytokine storm and complement cascade hyperactivation. It is common to observe diffuse microvascular thrombi in multiple organs, mostly in pulmonary microvessels. Thrombotic risk seems to be directly related to disease severity and worsens patients’ prognosis. Therefore, the correct understanding of the mechanisms underlying COVID-19 induced prothrombotic state can lead to a thorough assessment of the possible management strategies. Hence, we review the pathogenesis and therapy of COVID 19-related thrombosis disease, focusing on the available evidence on the possible treatment strategies and proposing an algorithm for the anticoagulation strategy based on disease severity.

Cite

CITATION STYLE

APA

Carfora, V., Spiniello, G., Ricciolino, R., Di Mauro, M., Migliaccio, M. G., Mottola, F. F., … Russo, M. G. (2021, April 1). Anticoagulant treatment in COVID-19: a narrative review. Journal of Thrombosis and Thrombolysis. Springer. https://doi.org/10.1007/s11239-020-02242-0

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free